Cargando…
Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study
We investigated serum total antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain after BNT162b2 mRNA vaccination against coronavirus disease 2019 (COVID-19) in Japanese patients taking various immunosuppressive medications for rhe...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592140/ https://www.ncbi.nlm.nih.gov/pubmed/36281134 http://dx.doi.org/10.1097/MD.0000000000031288 |
_version_ | 1784814856559394816 |
---|---|
author | Sugihara, Koichi Wakiya, Risa Kameda, Tomohiro Shimada, Hiromi Nakashima, Shusaku Kato, Mikiya Miyagi, Taichi Ushio, Yusuke Mizusaki, Mao Mino, Rina Chujo, Kanako Nomura, Yumi Inoo, Masayuki Kadowaki, Norimitsu Dobashi, Hiroaki |
author_facet | Sugihara, Koichi Wakiya, Risa Kameda, Tomohiro Shimada, Hiromi Nakashima, Shusaku Kato, Mikiya Miyagi, Taichi Ushio, Yusuke Mizusaki, Mao Mino, Rina Chujo, Kanako Nomura, Yumi Inoo, Masayuki Kadowaki, Norimitsu Dobashi, Hiroaki |
author_sort | Sugihara, Koichi |
collection | PubMed |
description | We investigated serum total antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain after BNT162b2 mRNA vaccination against coronavirus disease 2019 (COVID-19) in Japanese patients taking various immunosuppressive medications for rheumatic disease. In 212 outpatients with rheumatic diseases at Kagawa University Hospital and 43 healthy volunteers (controls), all of whom had received 2 doses of BNT162b2 vaccine, serum antibody titers of SARS-CoV-2 spike protein were analyzed at least 14 days after the second dose. Many of the patients were taking immunosuppressive agents to manage their rheumatic disease. The antibody titers against SARS-CoV-2 spike protein in these patients were significantly lower than those in controls. The analysis of therapeutic agents revealed that the antibody titers in patients treated with rituximab were much lower than those in controls. In patients treated with tacrolimus, baricitinib, azathioprine, mycophenolate mofetil, abatacept, tumor necrosis factor inhibitors, cyclosporine, interleukin-6 inhibitors, methotrexate, or glucocorticoids, antibody titers were moderately lower than those of controls. Interleukin-17 and interleukin-23 inhibitors did not impair the humoral response. In addition, the combination of methotrexate with various immunosuppressive agents reduced titers, although not significantly. In Japanese patients with rheumatic disease, many immunosuppressants impaired the immune response to the BNT162b2 vaccine. The degree of decline in antibody titers differed according to immunosuppressant. When used concomitantly with other immunosuppressants, methotrexate may impair the immune response to the BNT162b2 vaccine. However, immunomodulatory treatments such as interleukin-17 and -23 inhibitors may not attenuate this response in patients with rheumatic disease. |
format | Online Article Text |
id | pubmed-9592140 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-95921402022-10-25 Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study Sugihara, Koichi Wakiya, Risa Kameda, Tomohiro Shimada, Hiromi Nakashima, Shusaku Kato, Mikiya Miyagi, Taichi Ushio, Yusuke Mizusaki, Mao Mino, Rina Chujo, Kanako Nomura, Yumi Inoo, Masayuki Kadowaki, Norimitsu Dobashi, Hiroaki Medicine (Baltimore) 6900 We investigated serum total antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain after BNT162b2 mRNA vaccination against coronavirus disease 2019 (COVID-19) in Japanese patients taking various immunosuppressive medications for rheumatic disease. In 212 outpatients with rheumatic diseases at Kagawa University Hospital and 43 healthy volunteers (controls), all of whom had received 2 doses of BNT162b2 vaccine, serum antibody titers of SARS-CoV-2 spike protein were analyzed at least 14 days after the second dose. Many of the patients were taking immunosuppressive agents to manage their rheumatic disease. The antibody titers against SARS-CoV-2 spike protein in these patients were significantly lower than those in controls. The analysis of therapeutic agents revealed that the antibody titers in patients treated with rituximab were much lower than those in controls. In patients treated with tacrolimus, baricitinib, azathioprine, mycophenolate mofetil, abatacept, tumor necrosis factor inhibitors, cyclosporine, interleukin-6 inhibitors, methotrexate, or glucocorticoids, antibody titers were moderately lower than those of controls. Interleukin-17 and interleukin-23 inhibitors did not impair the humoral response. In addition, the combination of methotrexate with various immunosuppressive agents reduced titers, although not significantly. In Japanese patients with rheumatic disease, many immunosuppressants impaired the immune response to the BNT162b2 vaccine. The degree of decline in antibody titers differed according to immunosuppressant. When used concomitantly with other immunosuppressants, methotrexate may impair the immune response to the BNT162b2 vaccine. However, immunomodulatory treatments such as interleukin-17 and -23 inhibitors may not attenuate this response in patients with rheumatic disease. Lippincott Williams & Wilkins 2022-10-21 /pmc/articles/PMC9592140/ /pubmed/36281134 http://dx.doi.org/10.1097/MD.0000000000031288 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | 6900 Sugihara, Koichi Wakiya, Risa Kameda, Tomohiro Shimada, Hiromi Nakashima, Shusaku Kato, Mikiya Miyagi, Taichi Ushio, Yusuke Mizusaki, Mao Mino, Rina Chujo, Kanako Nomura, Yumi Inoo, Masayuki Kadowaki, Norimitsu Dobashi, Hiroaki Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study |
title | Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study |
title_full | Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study |
title_fullStr | Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study |
title_full_unstemmed | Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study |
title_short | Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study |
title_sort | humoral immune response against bnt162b2 mrna covid-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: a japanese monocentric study |
topic | 6900 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592140/ https://www.ncbi.nlm.nih.gov/pubmed/36281134 http://dx.doi.org/10.1097/MD.0000000000031288 |
work_keys_str_mv | AT sugiharakoichi humoralimmuneresponseagainstbnt162b2mrnacovid19vaccineinpatientswithrheumaticdiseaseundergoingimmunosuppressivetherapyajapanesemonocentricstudy AT wakiyarisa humoralimmuneresponseagainstbnt162b2mrnacovid19vaccineinpatientswithrheumaticdiseaseundergoingimmunosuppressivetherapyajapanesemonocentricstudy AT kamedatomohiro humoralimmuneresponseagainstbnt162b2mrnacovid19vaccineinpatientswithrheumaticdiseaseundergoingimmunosuppressivetherapyajapanesemonocentricstudy AT shimadahiromi humoralimmuneresponseagainstbnt162b2mrnacovid19vaccineinpatientswithrheumaticdiseaseundergoingimmunosuppressivetherapyajapanesemonocentricstudy AT nakashimashusaku humoralimmuneresponseagainstbnt162b2mrnacovid19vaccineinpatientswithrheumaticdiseaseundergoingimmunosuppressivetherapyajapanesemonocentricstudy AT katomikiya humoralimmuneresponseagainstbnt162b2mrnacovid19vaccineinpatientswithrheumaticdiseaseundergoingimmunosuppressivetherapyajapanesemonocentricstudy AT miyagitaichi humoralimmuneresponseagainstbnt162b2mrnacovid19vaccineinpatientswithrheumaticdiseaseundergoingimmunosuppressivetherapyajapanesemonocentricstudy AT ushioyusuke humoralimmuneresponseagainstbnt162b2mrnacovid19vaccineinpatientswithrheumaticdiseaseundergoingimmunosuppressivetherapyajapanesemonocentricstudy AT mizusakimao humoralimmuneresponseagainstbnt162b2mrnacovid19vaccineinpatientswithrheumaticdiseaseundergoingimmunosuppressivetherapyajapanesemonocentricstudy AT minorina humoralimmuneresponseagainstbnt162b2mrnacovid19vaccineinpatientswithrheumaticdiseaseundergoingimmunosuppressivetherapyajapanesemonocentricstudy AT chujokanako humoralimmuneresponseagainstbnt162b2mrnacovid19vaccineinpatientswithrheumaticdiseaseundergoingimmunosuppressivetherapyajapanesemonocentricstudy AT nomurayumi humoralimmuneresponseagainstbnt162b2mrnacovid19vaccineinpatientswithrheumaticdiseaseundergoingimmunosuppressivetherapyajapanesemonocentricstudy AT inoomasayuki humoralimmuneresponseagainstbnt162b2mrnacovid19vaccineinpatientswithrheumaticdiseaseundergoingimmunosuppressivetherapyajapanesemonocentricstudy AT kadowakinorimitsu humoralimmuneresponseagainstbnt162b2mrnacovid19vaccineinpatientswithrheumaticdiseaseundergoingimmunosuppressivetherapyajapanesemonocentricstudy AT dobashihiroaki humoralimmuneresponseagainstbnt162b2mrnacovid19vaccineinpatientswithrheumaticdiseaseundergoingimmunosuppressivetherapyajapanesemonocentricstudy |